Four-Year Analysis of Platinum and Anthracycline Combination for Ovarian Cancer

Abstract

Eighty-nine patients with advanced ovarian cancer have been treated with a combination of cis-platinum (50 mg/m²) + an anthracycline (adriamycin 50 mg/m² in 26 patients, or epirubicin 60 mg/m² in 63 patients). The treatment was repeated every 28 days for a maximum of 12 cycles. Seventy-nine were evaluable for response. CR was achieved in 19 (24%) patients (2 clinical and 17 after a second-look evaluation) and a PR in 31 (39%) for an estimated median duration of 43 and 10 months, respectively. Nine patients who achieved CR and 2 out of 10 non-evaluable patients were alive without any evidence of disease after a median follow-up of 36 months (range 29–53). The treatment was generally well tolerated. The multivariate actuarial 4-year analysis by Cox’s proportional hazards model shows that residual tumor and performance status have an independent prognostic value on survival. The combination of CP + an anthracycline (and in particular epirubicin) is an effective and generally well tolerated treatment for ovarian cancer. Only patients with initial minimal residual disease and achieving CR are candidates for long-term survival.

Effect of combined treatment with the epirubicin‐incorporating micelles (NC‐6300) and 1,2‐diaminocyclohexane platinum (II)‐incorporating micelles (NC‐4016) on a human gastric cancer model

“…Co-administration of anthracycline-based topoisomerase II inhibitors and platinum-based DNA-modifying agents is widely used in clinical practice. 13,30,31 The synergism between these two classes of drugs can be explained by the reciprocal interaction in which the inhibition of topoisomerase II partially hinders the efficient repair of DNA damaged by platinum alkylating agents. [32][33][34] In the present study, NCs exhibited synergistic activity equivalent to E/O.…”

Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy

“…Because the inhibition of TOP2 can partially hinder the efficient repair of DNA damaged by platinum alkylating agents, synergism will arise when the two drugs are co-administered [1][2][3][4]. Enhanced tumor responses are often observed in patients with ovarian cancer or advanced breast cancer in comparison to single use of these two drugs [5,6]. For example, co-administration of cisplatin (CDDP) and doxorubicin has improved the therapeutic efficacy in a phase III clinical trial in endometrial carcinoma [7].…”

Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy

“…Hence, most clinical regimens comprise multiple non-cross-resistant anticancer agents . Among all available chemotherapeutic agents, the most commonly used are arguably anthracycline and platinum-based drugs. , In the few cases where these two classes of drugs have been combined, enhanced tumor responses were observed in patients with ovarian cancer, advanced breast cancer, and endometrial carcinoma, thus emphasizing the potential of this drug combination in the treatment of cancer.…”